Form 4: 180 Life Sciences Director Stephen Shoemaker Granted Equity Compensation

Stephen H. Shoemaker, a Director of 180 Life Sciences Corp., was granted 72,297 restricted common stock shares and 165,000 non-qualified stock options as compensation for his board service.

Summary

• Stephen H. Shoemaker, a Director of 180 Life Sciences Corp. (ATNF), was granted equity compensation on June 17, 2025.
• The compensation includes 72,297 shares of common stock, issued as restricted stock shares subject to time-based vesting.
• These restricted shares will vest in two equal tranches: 1/2 on December 17, 2025, and 1/2 on June 17, 2026, contingent on Mr. Shoemaker's continued service.
• The restricted stock was issued under the Issuer's 2022 Equity Compensation Plan.
• Additionally, Mr. Shoemaker received 165,000 non-qualified stock options with an exercise price of $0.929 per share.
• These options also vest in two equal tranches: 1/2 on December 17, 2025, and 1/2 on June 17, 2026, subject to continued service.
• The options have an expiration date of June 17, 2035.
• The options were issued under the Issuer's 2025 Option Incentive Plan, which requires stockholder approval; options cannot be exercised prior to approval and will be cancelled if approval is not obtained.
• Both the restricted stock and options were granted in consideration for services rendered and agreed to be rendered as a member of the Board of Directors.

Sentiment

Score: 6

Explanation: The document reports a routine equity compensation grant to a director, which is generally a neutral to slightly positive event as it aligns interests, but carries the risk of plan approval for the options.

Positives

• The grant of equity compensation aligns the Director's interests with those of the shareholders, incentivizing long-term performance.
• The compensation package reflects the company's commitment to attracting and retaining experienced board members.

Negatives

• The options are subject to stockholder approval of the 2025 Option Incentive Plan, introducing uncertainty regarding their ultimate validity.
• The compensation is non-cash, meaning no immediate liquidity for the recipient, and its value is tied to future stock performance.

Risks

• The 2025 Option Incentive Plan, under which 165,000 stock options were granted, is subject to stockholder approval; if approval is not obtained, these options will be cancelled.
• The vesting of both restricted stock and options is contingent upon the recipient's continued service to the Issuer, meaning forfeiture if service ceases before vesting dates.
• The value of the equity compensation is subject to market fluctuations of 180 Life Sciences Corp.'s stock price.

Future Outlook

The future outlook for the granted equity compensation is dependent on the company's stock performance and the successful stockholder approval of the 2025 Option Incentive Plan. Vesting of both restricted stock and options is scheduled for December 17, 2025, and June 17, 2026, contingent on continued service.

Management Comments

• The restricted stock shares and non-qualified stock options were issued to the Reporting Person in consideration for services rendered and agreed to be rendered to the Issuer as a member of the Board of Directors of the Issuer.

Industry Context

This filing represents a standard practice in corporate governance where directors receive equity compensation to align their long-term interests with those of the company's shareholders. Such grants are common across various industries, particularly in biotechnology and life sciences, to incentivize leadership and retention.

Corporate Governance

Related Party Transactions

• The grant of 72,297 restricted common stock shares and 165,000 non-qualified stock options to Stephen H. Shoemaker, a Director of the Issuer, constitutes a related party transaction as it involves compensation to a member of the company's board.

Stakeholder Impact

• Shareholders: Potential for dilution from the issuance of new shares upon vesting and exercise, but also potential for increased value through aligned director incentives.
• Employees: No direct impact mentioned for general employees, but the existence of equity compensation plans can set precedents for broader employee incentive programs.
• Director (Stephen H. Shoemaker): Receives significant equity compensation, aligning his financial interests with the company's long-term success, subject to vesting and plan approval.

Next Steps

• Stockholders of 180 Life Sciences Corp. will need to approve the 2025 Option Incentive Plan for the granted options to become exercisable and avoid cancellation.
• The restricted stock and options will vest in tranches on December 17, 2025, and June 17, 2026, subject to continued service.

Key Dates

Keywords

SEC Form 4, Insider Trading, Equity Compensation, Restricted Stock, Stock Options, Director Compensation, 180 Life Sciences Corp., ATNF, Corporate Governance, Vesting Schedule